EGFR and neoplasm: In a multivariate analysis using this criteria, EGFR FISH positive tumour status demonstrated significantly improved response rates (36 % in EGFR FISH positive versus 3 % in EGFR FISH negative patients; p < 0.001) and overall survival (median overall survival 18.7 months in EGFR FISH positive versus 7.0 months in EGFR FISH negative patients; p = 0.003) in 103 patients with non-small cell lung cancer being treated with the EGFR tyrosine kinase inhibitor gefitinib.